PRRUF — IMMUTEP Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1506184 ·
Last close
$0.02
Market Cap
$29.47M
52W High
$0.33
52W Low
$0.02
ADV30
673
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 83,267,229 | 63,672,558 | 21,734,183 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | — | — | — | — | 147,201,896 | 72,747,858 | 48,303,108 |
| Mar 2025 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-520,796,399
Inventory
—
Receivables
$9,623,374
ST Investments
$5,200,486
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$19,934,102
EBITDA
$-79,403,952
Free Cash Flow
$-36,994,360
Enterprise Value
$-11,971,481
Total Cash
$68,873,040
Total Debt
$1,047,526
Shares Out
1,473,721,306
Trailing EPS
$-0.04
Book Value
$0.05
ROE
-77.3%
ROA
-42.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 14,556,923 | -81,592,146 | -79,304,563 | 83,267,229 | 21,734,183 | 61,533,046 | — |
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 0 | -46,557,462 | -42,716,625 | 201,579,281 | 12,057,539 | 189,521,742 | — |
| Jun 2023 | 0 | -41,431,305 | -39,896,348 | 147,448,990 | 10,979,601 | 136,469,389 | — |
| Jun 2022 | 170,369 | -33,837,338 | -32,210,826 | 102,169,550 | 8,092,184 | 94,077,366 | -43,944,386 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NNVC | NANOVIRICIDES, INC. | $29.61M | $1.16 | — |
| AYTU | AYTU BIOPHARMA, INC | $28.91M | $2.66 | — |
| RDPTF | Radiopharm Theranostics Ltd | $28.89M | $0.01 | — |
| PMN | ProMIS Neurosciences Inc. | $28.88M | $3.21 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $30.24M | $0.18 | — |
News headlines (Yahoo Finance, 1h cache)
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
2026-11-19 00:12 · Yahoo
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
2026-11-10 23:48 · Yahoo
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
2026-11-08 22:34 · Yahoo
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
2026-11-05 13:00 · Yahoo
Immutep Quarterly Activities Report Q1 FY27
2026-10-29 12:00 · Yahoo
Immutep Receives A$2.16 million French R&D Tax Incentive
2026-10-28 12:00 · Yahoo
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
2026-10-23 12:00 · Yahoo
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
2026-10-19 12:00 · Yahoo
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
2026-10-14 12:00 · Yahoo
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-10-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.